Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
NOVEMBER 17, 2022
Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016. Medicare’s National Coverage Determination for Aducanumab – A One-Off or a Pragmatic Path Forward? Reforming the World Health Organization’s Essential Medicines List: Essential but Unaffordable.
Let's personalize your content